Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study

References

• Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48:251-9; PMID:11156649; https://doi.org/10.1136/gut.48.2.251
   PubMed Web of Science ®Google Scholar
• Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31:330-5; PMID:10655254; https://doi.org/10.1002/hep.510310211
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; https://doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995; 221:291-8; PMID:7717783
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148:1383-91 e6; PMID:25747273; https://doi.org/10.1053/j.gastro.2015.02.055
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2; PMID:21374666; https://doi.org/10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Verslype C, Rosmorduc O, Rougier P, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7):vii41-8; https://doi.org/10.1093/annonc/mds225
   PubMed Web of Science ®Google Scholar
• European Association for The Study of The Liver, European Organisation for Research Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-43; PMID:22424438; https://doi.org/10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; https://doi.org/10.1038/32588
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 2015; 350:972-8; PMID:26516201; https://doi.org/10.1126/science.aad0779
   PubMed Web of Science ®Google Scholar
• Palucka AK, Coussens LM. The Basis of Oncoimmunology. Cell 2016; 164:1233-47; PMID:26967289; https://doi.org/10.1016/j.cell.2016.01.049
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; https://doi.org/10.1016/j.immuni.2013.07.004
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32; PMID:9500607; https://doi.org/10.1038/nm0398-328
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318; https://doi.org/10.1200/JCO.2000.18.23.3894
   PubMed Web of Science ®Google Scholar
• Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161:777-82; PMID:10022683; https://doi.org/10.1016/S0022-5347(01)61767-1 10.1097/00005392-199903000-00009
   PubMed Web of Science ®Google Scholar
• Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28:496-504; PMID:16113606; https://doi.org/10.1097/01.cji.0000171291.72039.e2
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006; 12:2817-25; PMID:16675576; https://doi.org/10.1158/1078-0432.CCR-05-2856
   PubMed Web of Science ®Google Scholar
• Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009; 49:124-32; PMID:18980227; https://doi.org/10.1002/hep.22626
   PubMed Web of Science ®Google Scholar
• Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, Jung NC, Lee WB, Lee HS, Bae YS et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012; 41:1601-9; PMID:22971679; https://doi.org/10.3892/ijo.2012.1626
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015; 113:1666-76; PMID:26657650; https://doi.org/10.1038/bjc.2015.430
   PubMed Web of Science ®Google Scholar
• Apetoh L, Locher C, Ghiringhelli F, Kroemer G, Zitvogel L. Harnessing dendritic cells in cancer. Semin Immunol 2011; 23:42-9; PMID:21295491; https://doi.org/10.1016/j.smim.2011.01.003
   PubMed Web of Science ®Google Scholar
• Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23:146-52; PMID:20970973; https://doi.org/10.1016/j.coi.2010.09.008
   PubMed Web of Science ®Google Scholar
• Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q, Wong OH, Lo CK, Ng IO, Chan LC et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol 2007; 179:6009-15; PMID:17947674; https://doi.org/10.4049/jimmunol.179.9.6009
   PubMed Web of Science ®Google Scholar
• Kim D, Jeon C, Kim JH, Kim MS, Yoon CH, Choi IS, Kim SH, Bae YS. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res 2006; 312:1277-88; PMID:16466653; https://doi.org/10.1016/j.yexcr.2005.12.029
   PubMed Web of Science ®Google Scholar
• Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A et al. Precision measurement of the helium flux in primary cosmic rays of rigidities 1.9 GV to 3 TV with the alpha magnetic spectrometer on the international space station. Phys Rev Lett 2015; 115:211101; PMID:26636836; https://doi.org/10.1103/PhysRevLett.115.211101
   PubMed Web of Science ®Google Scholar
• Lappin MB, Weiss JM, Delattre V, Mai B, Dittmar H, Maier C, Manke K, Grabbe S, Martin S, Simon JC. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999; 98:181-8; PMID:10540216; https://doi.org/10.1046/j.1365-2567.1999.00850.x
   PubMed Web of Science ®Google Scholar
• Okada N, Tsujino M, Hagiwara Y, Tada A, Tamura Y, Mori K, Saito T, Nakagawa S, Mayumi T, Fujita T et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001; 84:1564-70; PMID:11384109; https://doi.org/10.1054/bjoc.2001.1801
   PubMed Web of Science ®Google Scholar
• Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 2006; 176:157-64; PMID:16365406; https://doi.org/10.4049/jimmunol.176.1.157
   PubMed Web of Science ®Google Scholar
• Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014; 134:342-51; PMID:23825037; https://doi.org/10.1002/ijc.28372
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF, Ferrari C et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66:1139-46; PMID:16424051; https://doi.org/10.1158/0008-5472.CAN-05-2244
   PubMed Web of Science ®Google Scholar
• Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 1997; 90:2804-9; PMID:9326248
   PubMed Web of Science ®Google Scholar
• Ohteki T, Tada H, Ishida K, Sato T, Maki C, Yamada T, Maki C, Yamada T, Hamuro J, Koyasu S. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo. J Exp Med 2006; 203:2329-38; PMID:16966429; https://doi.org/10.1084/jem.20061297
   PubMed Web of Science ®Google Scholar
• Mueller K, Schweier O, Pircher H. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Euro J Immunol 2008; 38:2874-85; PMID:18825743; https://doi.org/10.1002/eji.200838426
   PubMed Web of Science ®Google Scholar
• Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2013; 19:106-17; PMID:23149818; https://doi.org/10.1158/1078-0432.CCR-12-2143
   PubMed Web of Science ®Google Scholar
• Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015; 33:74-82; PMID:25403209; https://doi.org/10.1200/JCO.2014.57.3329
   PubMed Web of Science ®Google Scholar
• Xu A, Bhanumathy KK, Wu J, Ye Z, Freywald A, Leary SC, Li R, Xiang J. IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. Cell Biosci 2016; 6:30; PMID:27158441; https://doi.org/10.1186/s13578-016-0098-2
   PubMed Web of Science ®Google Scholar
• Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O'Reilly RJ. Soluble and membrane bound IL-15 Ralpha/IL-15 complexes mediate proliferation of high avidity central memory CD8+ T-cells for adoptive immunotherapy of cancer and infections. Clin Exp Immunol 2016; 186(2):249-65; PMID:27227483; https://doi.org/10.1111/cei.12816
   PubMed Web of Science ®Google Scholar
• Huarte E, Fisher J, Turk MJ, Mellinger D, Foster C, Wolf B, Meehan KR, Fadul CE, Ernstoff MS. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett 2009; 285:80-8; PMID:19501956; https://doi.org/10.1016/j.canlet.2009.05.003
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257:107-26; PMID:24329793; https://doi.org/10.1111/imr.12131
   PubMed Web of Science ®Google Scholar
• Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res 2015; 75:5187-93; PMID:26627006; https://doi.org/10.1158/0008-5472.CAN-15-1498
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711; PMID:18477802; https://doi.org/10.1093/jnci/djn134 10.1093/jnci/djn342
   PubMed Web of Science ®Google Scholar
• Korean Association for the Study of the L. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012; 18:109-62; PMID:22893865; https://doi.org/10.3350/cmh.2012.18.2.109
   PubMedGoogle Scholar
• Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012; 37:1-2; PMID:22840835; https://doi.org/10.1016/j.immuni.2012.07.010
   PubMed Web of Science ®Google Scholar